Bortezomib is FDA-approved for use in the initial treatment of multiple myeloma in combination with cyclophosphamide and dexamethasone. It is also FDA-approved for use in the treatment of multiple myeloma in individuals who previously responded to bortezomib and relapsed at least six months after the completion of the prior treatment. Also, it is FDA-approved for use in the treatment of mantle cell lymphoma in individuals who have received at least one prior first-line treatment.

**Non-FDA-Approved Uses**

- Treatment of antibody-mediated rejection in cardiac transplantation

- Relapsed or refractory cutaneous T-cell lymphomas

- Relapsed or refractory follicular lymphoma

- Relapsed or refractory peripheral T-cell lymphoma

- Systemic light-chain amyloidosis

- Relapsed or refractory Waldenstrom macroglobulinemia